U.S. markets open in 5 hours 47 minutes
  • S&P Futures

    4,228.00
    +18.25 (+0.43%)
     
  • Dow Futures

    33,432.00
    +128.00 (+0.38%)
     
  • Nasdaq Futures

    13,374.25
    +63.00 (+0.47%)
     
  • Russell 2000 Futures

    1,986.70
    +10.40 (+0.53%)
     
  • Crude Oil

    94.44
    +0.10 (+0.11%)
     
  • Gold

    1,806.40
    -0.80 (-0.04%)
     
  • Silver

    20.35
    +0.01 (+0.03%)
     
  • EUR/USD

    1.0305
    -0.0020 (-0.20%)
     
  • 10-Yr Bond

    2.8880
    0.0000 (0.00%)
     
  • Vix

    20.23
    +0.49 (+2.48%)
     
  • GBP/USD

    1.2191
    -0.0012 (-0.10%)
     
  • USD/JPY

    133.3300
    +0.3310 (+0.25%)
     
  • BTC-USD

    23,944.28
    -638.73 (-2.60%)
     
  • CMC Crypto 200

    568.45
    -6.29 (-1.09%)
     
  • FTSE 100

    7,486.01
    +20.10 (+0.27%)
     
  • Nikkei 225

    28,546.98
    +727.65 (+2.62%)
     

UPDATE 1-Novartis leans toward spinoff of generic drugs unit - Bloomberg News

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

(Adds Novartis response)

June 30 (Reuters) - Novartis prefers a spinoff of its generic drug unit over a potential sale to private equity firms, Bloomberg News reported on Thursday, citing people familiar with the matter.

A challenging macro environment for leveraged buyouts has made the sale route difficult and Novartis sees a separate listing of the Sandoz business as more likely, the report said. (https://bloom.bg/3yt7Iu2)

The Swiss pharmaceutical group in October said it had started a strategic review of the Sandoz unit as price pressures mounted in the off-patent drug sector.

On Thursday, Novartis reiterated its previous statement that "the strategic review is ongoing, all options remain on the table and the company plans to provide an update before the end of the year". (Reporting by Manas Mishra in Bengaluru; Editing by Devika Syamnath)